

**SENATE . . . . . No. 800**

---

**The Commonwealth of Massachusetts**

\_\_\_\_\_

PRESENTED BY:

***Michael O. Moore***

\_\_\_\_\_

*To the Honorable Senate and House of Representatives of the Commonwealth of Massachusetts in General Court assembled:*

The undersigned legislators and/or citizens respectfully petition for the adoption of the accompanying bill:

An Act relative to pharmacists as healthcare providers.

\_\_\_\_\_

PETITION OF:

NAME:	DISTRICT/ADDRESS:	
<i>Michael O. Moore</i>	<i>Second Worcester</i>	
<i>Bruce E. Tarr</i>	<i>First Essex and Middlesex</i>	<i>12/2/2025</i>

**SENATE . . . . . No. 800**

---

By Mr. Moore, a petition (accompanied by bill, Senate, No. 800) of Michael O. Moore for legislation relative to pharmacists as healthcare providers. Financial Services.

---

[SIMILAR MATTER FILED IN PREVIOUS SESSION  
SEE SENATE, NO. 1425 OF 2023-2024.]

**The Commonwealth of Massachusetts**

\_\_\_\_\_  
**In the One Hundred and Ninety-Fourth General Court  
(2025-2026)**  
\_\_\_\_\_

An Act relative to pharmacists as healthcare providers.

*Be it enacted by the Senate and House of Representatives in General Court assembled, and by the authority of the same, as follows:*

1           To provide for the development of a statewide protocol for health condition testing,  
2 screening, and treatment by pharmacists for qualified conditions.

3           (a) Pursuant to a statewide written protocol approved by the Division of Public Health, a  
4 pharmacist may order, test, screen, and treat health conditions that include all of the following:

5           (1) The list of qualified conditions for testing, screening, and treatment or therapy shall  
6 include Influenza, Streptococcal infections, COVID-19 or any other emerging and existing  
7 public health threats identified by the Division of Public Health if permitted by an order, rule, or  
8 regulation.

9           (2) A pharmacist who orders, tests, screens, or treats health conditions under this section  
10 may use any test that may guide clinical decision making that is waived under the federal

11 Clinical Laboratory Improvement Amendments of 1988, or 51 the federal rules adopted  
12 thereunder, or any established screening procedure that is established via a statewide protocol.

13 (3) A pharmacist may delegate the administrative and technical tasks of performing a test  
14 waived by the federal Clinical Laboratory Improvement Amendments of 1988 to an intern or  
15 pharmacy technician acting under the supervision of the pharmacist.

16 (4) This section prohibits the denial of reimbursement under health benefit plans for  
17 services and procedures performed by a pharmacist that are within the scope of the pharmacist's  
18 license and would be covered if the services or procedures were performed by a physician, an  
19 advanced practice nurse, or physician's assistant. Thus, an insurance carrier and/or pharmacy  
20 benefit manager shall develop adequate provider and consult codes as authorized by this act for  
21 pharmacy compensation.